Titre | A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse |
Protocole ID | CA209-914 |
ClinicalTrials.gov ID | NCT03138512 |
Type(s) de cancer | Rein |
Phase | Phase III |
Stade | Adjuvant |
Type étude | Traitement |
Médicament | nivolumab et ipilimumab |
Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Ville | Montréal |
Investigateur(trice) principal(e) |
Dr Fred Saad |
Coordonnateur(trice) |
Amal Nadiri 514-890-8000 poste 26074 |
Statut | Fermé |
Critètes d'éligibilité |
|
Critètes d'exclusion |
|